Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Samuel SangMehreen S DatooEdward OtienoCharles MuiruriDuncan BellamyEmmaloise GathuriOmar NgotoJanet MusembiSam Provstgaard-MorysLisa StockdaleJeremy AboagyeDaniel WoodsAlison LawrieRacheal RobertsKelvias KeterDomtila KimaniFrancis M NdunguMelissa C KapuluIrene NjauBenedict OrindiKatie J EwerAdrian V S HillPhilip BejonMainga M HamalubaPublished in: Wellcome open research (2023)
May 2021).